Unicycive Therapeutics Inc
UNCY6.340USD
+5.672+849.81%
종가 06/20, 16:00（ET）시세는 15분 지연됩니다
759.21M시가총액
손실P/E TTM
자세한 내용은 Unicycive Therapeutics Inc 회사
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
회사 정보
종목 코드 UNCY
회사 이름Unicycive Therapeutics Inc
상장일Jun 17, 2021
설립일2016
CEODr. Shalabh Gupta, M.D.
직원 수22
유형Ordinary Share
회계 연도 종료Jun 17
주소4300 El Camino Real, Suite 210
도시LOS ALTOS
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94022
전화16503840642
웹사이트https://unicycive.com/
종목 코드 UNCY
상장일Jun 17, 2021
설립일2016
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Thu, May 15
마지막 업데이트: Thu, May 15
주주
주주 유형
주주
주주
비율
Vivo Capital, LLC
0.94%
Great Point Partners, LLC
0.91%
Octagon Capital Advisors LP
0.83%
Nantahala Capital Management, LLC
0.78%
Gupta (Shalabh K)
0.50%
Other
96.04%
주주
주주
비율
Vivo Capital, LLC
0.94%
Great Point Partners, LLC
0.91%
Octagon Capital Advisors LP
0.83%
Nantahala Capital Management, LLC
0.78%
Gupta (Shalabh K)
0.50%
Other
96.04%
주주 유형
주주
비율
Hedge Fund
3.68%
Venture Capital
1.37%
Individual Investor
0.52%
Investment Advisor/Hedge Fund
0.17%
Investment Advisor
0.01%
Research Firm
0.01%
Other
94.23%
기관 주식 보유
마지막 업데이트: Tue, Mar 4
마지막 업데이트: Tue, Mar 4
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
61
68.99M
57.19%
+435.46K
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
2023Q1
38
9.94M
65.95%
+1.31M
2022Q4
33
9.05M
60.10%
+325.03K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Vivo Capital, LLC
9.97M
8.33%
--
--
Dec 31, 2024
Great Point Partners, LLC
10.98M
9.17%
+2.42M
+28.29%
Dec 31, 2024
Octagon Capital Advisors LP
10.00M
8.35%
+1.44M
+16.84%
Dec 31, 2024
Nantahala Capital Management, LLC
10.39M
8.68%
+7.57M
+268.46%
Dec 31, 2024
Gupta (Shalabh K)
5.97M
4.99%
--
--
Apr 25, 2024
Logos Global Management LP
5.08M
4.24%
--
--
Dec 31, 2024
Walleye Capital LLC
5.00M
4.18%
--
--
Dec 31, 2024
SilverArc Capital Management, LLC
2.49M
2.08%
-1.51M
-37.83%
Dec 31, 2024
Acuta Capital Partners, LLC
2.30M
1.92%
+323.80K
+16.36%
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Fri, Jun 6
마지막 업데이트: Fri, Jun 6
이름
비율
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
